Trial · NCT07413562
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 27 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Serum tau level | Baseline (Day 7 after injury) and 1 month after injury. | Serum tau concentration will be measured as a biomarker of neuronal injury, where higher levels may indicate greater neuronal damage. |
| Secondary | Serum amyloid-β (Aβ) level | Baseline (Day 7 after injury) and 1 month after injury. | Serum amyloid-β (Aβ) concentration will be measured as a biomarker related to cognitive impairment, where higher levels may indicate increased pathological burden. |
| Secondary | Serum glial fibrillary acidic protein (GFAP) level | Baseline (Day 7 after injury) and 1 month after injury. | Serum GFAP concentration will be measured as a biomarker of astroglial injury, where higher levels may indicate greater glial damage. |
| Secondary | Serum S100β level | Baseline (Day 7 after injury) and 1 month after injury. | Serum S100β concentration will be measured as a biomarker of blood-brain barrier disruption and glial injury, where higher levels may indicate worse neurological injury. |
| Secondary | Serum α-synuclein level | Baseline (Day 7 after injury) and 1 month after injury. | Serum α-synuclein concentration will be measured as a biomarker related to neuronal degeneration, where higher levels may indicate greater neuronal pathology. |
| Other | Feasibility outcomes | From baseline (Day 7 after injury) to 3 months after injury. | Feasibility will be evaluated by enrollment rate, recruitment rate, adherence rate (proportion of completed scheduled stimulation hours), and retention rate (completion of all outcome assessments). |
| Other | Safety outcomes | From baseline (Day 7 after injury) to 3 months after injury. | Adverse events related to the intervention (e.g., skin pain, uncomfortable cutaneous sensations, dizziness, abnormal blood pressure, or heart rhythm disturbances) will be recorded. Side effects will be monitored using a 10-item Likert-scale questionnaire (score range: 1 = absent to 5 = severe). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07413562/registered?page=2